These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33368732)

  • 1. The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation.
    Yang P; Zhu X; Liang W; Cai R
    Mycoses; 2021 May; 64(5):495-502. PubMed ID: 33368732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
    Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
    Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
    Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
    BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
    Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
    Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes.
    Garg N; Jorgenson M; Descourouez J; Saddler CM; Parajuli S; Astor BC; Djamali A; Mandelbrot D
    BMC Nephrol; 2018 Nov; 19(1):332. PubMed ID: 30463516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and risk factors for late-onset pneumocystis jirovecii pneumonia in kidney transplantation recipients.
    Zhu X; Xie M; Fan J; Geng B; Fei G; Zhou Q; Wu H; Liu X; Jiang X
    Mycoses; 2024 Jan; 67(1):e13688. PubMed ID: 38214337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical descriptive analysis of severe
    Xie D; Xu W; You J; Yuan X; Li M; Bi X; Zhang K; Li H; Xian Y
    Bioengineered; 2021 Dec; 12(1):1264-1272. PubMed ID: 33896387
    [No Abstract]   [Full Text] [Related]  

  • 12. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
    Geerlinks AV; Campigotto A; Science M; Gupta S
    Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of predictive markers of Pneumocystis jirovecii pneumonia in kidney transplant recipients.
    Zhou J; Pan H; Zhang J; Luo L; Cao Y; Wang L; Cheng Z; Zhang G
    Transpl Immunol; 2024 Aug; 85():102074. PubMed ID: 38945175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
    McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with Pneumocystis jirovecii pneumonia.
    Lee S; Park Y; Kim SG; Ko EJ; Chung BH; Yang CW
    Microbiol Immunol; 2020 May; 64(5):356-365. PubMed ID: 31994768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-center retrospective analysis of Pneumocystis jirovecii pneumonia in patients after deceased donor renal transplantation.
    Zou J; Wang T; Qiu T; Zhou J; Chen Z; Ma X; Jin Z; Xu Y; Zhang L
    Transpl Immunol; 2022 Jun; 72():101593. PubMed ID: 35367619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.